Working… Menu

Prevalence of Thrombosis in COVID-Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04615026
Recruitment Status : Recruiting
First Posted : November 4, 2020
Last Update Posted : November 4, 2020
Information provided by (Responsible Party):
Alexander Hyhlik-Dürr, University Hospital Augsburg

Brief Summary:
Examination of the prevalence of thrombosis in COVID-patients, especially in an out-patient setting. Assessment by duplex sonography. If thrombosis is detected, we will correlate it with immunity status. Assessment of health issues and cognitive function as late complication after infection.

Condition or disease Intervention/treatment
Covid19 Diagnostic Test: duplex sonography

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 400 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 1 Day
Official Title: Prevalence of Thrombosis in COVID-Patients in Correlation to Humoral and Cellular Immunity
Actual Study Start Date : November 4, 2020
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : June 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Clots

Group/Cohort Intervention/treatment
COVID 19 patients
all patients with positive SARS-CoV 2 swap
Diagnostic Test: duplex sonography
all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
Other Names:
  • test of smell
  • cognitive test
  • blood sample

Primary Outcome Measures :
  1. prevalence of thrombosis [ Time Frame: 20 minutes ]

Secondary Outcome Measures :
  1. correlation to immunity [ Time Frame: 20 minutes ]
  2. Assessment of late complications [ Time Frame: 20 minutes ]

Biospecimen Retention:   Samples Without DNA
Aliquots for proteomics analysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
all SARS CoV 2 positive patients registered at local health departments (Augsburg) are invited to join the study

Inclusion Criteria:

  • SARS CoV 2 positive swap, at least 4 weeks after infection

Exclusion Criteria:

  • under 18 years old no consent anemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04615026

Layout table for location contacts
Contact: Yvonne Gosslau, MD +49821400161977
Contact: Alexander Hyhlik-Duerr, MD +498214002655

Layout table for location information
University Hospital Augsburg Recruiting
Augsburg, Germany, 86165
Contact: Yvonne Gosslau, MD    +49821400161977   
Contact: Alexander Hyhlik-Duerr, MD    +498214002655   
Sponsors and Collaborators
University Hospital Augsburg
Layout table for investigator information
Principal Investigator: Alexander Hyhlik-Duerr, MD University Hospital Augsburg
Layout table for additonal information
Responsible Party: Alexander Hyhlik-Dürr, Head of department, University Hospital Augsburg Identifier: NCT04615026    
Other Study ID Numbers: COVID Thrombose
First Posted: November 4, 2020    Key Record Dates
Last Update Posted: November 4, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: data as pseudonyms

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases